Olpasiran early access program
This program provides early access to a study drug called olpasiran, which may help lower cholesterol. Doctors can request it for patients who have no other treatment options and cannot join a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a doctor who can request the drug for you
- You must not be able to join a regular clinical trial
- You must have a serious or life-threatening condition that this drug might help
- You must not have any other treatment options available
- Your doctor must agree that the potential benefit outweighs the risks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
This study tests if a medication called olpasiran can lower a type of fat in your blood called Lp(a), which is linked to heart problems. You take the medicine or a placebo and get a special heart scan to see changes in your arteries.
This study tests an investigational drug called plozasiran for people with severely high triglycerides that have already caused pancreatitis (inflammation of the pancreas). The goal is to see if the drug can lower triglycerides and help prevent future attacks.
This study looks at how well the drug Olaparib works in real-world settings for patients with early breast cancer that is HER2-negative. It aims to better understand treatment outcomes.
This program provides early access to a Novartis study drug for patients with serious or life-threatening conditions who have no other treatment options. It aims to help patients who cannot join a clinical trial.
This program provides access to olverembatinib (also known as HQP1351) for patients who have no other treatment options and whose doctor believes the drug might help. The drug is given to patients individually under a special access program, not as part of a formal clinical trial.